Investing.com - Madrigal Pharma (NASDAQ: MDGL) reported first quarter EPS of $-4.23, $0.70 better than the analyst estimate of $-4.93. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.00.
Madrigal Pharma's stock price closed at $308.87. It is up 19.96% in the last 3 months and up 360.69% in the last 12 months.
Madrigal Pharma saw 3 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Madrigal Pharma's stock price’s past reactions to earnings here.
According to InvestingPro, Madrigal Pharma's Financial Health score is "weak performance".
Check out Madrigal Pharma's recent earnings performance, and Madrigal Pharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar